Survival-related profile, pathways, and transcription factors in ovarian cancer.

<h4>Background</h4>Ovarian cancer has a poor prognosis due to advanced stage at presentation and either intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials with different combinations and sequences of classic cytotoxic dr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Anne P G Crijns, Rudolf S N Fehrmann, Steven de Jong, Frans Gerbens, Gert Jan Meersma, Harry G Klip, Harry Hollema, Robert M W Hofstra, Gerard J te Meerman, Elisabeth G E de Vries, Ate G J van der Zee
Formato:	article
Lenguaje:	EN
Publicado:	Public Library of Science (PLoS) 2009
Materias:	Medicine R
Acceso en línea:	https://doaj.org/article/b4910f46b04e47b29451059654179ad5
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:b4910f46b04e47b29451059654179ad5
record_format	dspace
spelling	oai:doaj.org-article:b4910f46b04e47b29451059654179ad52021-11-25T05:37:22ZSurvival-related profile, pathways, and transcription factors in ovarian cancer.1549-12771549-167610.1371/journal.pmed.1000024https://doaj.org/article/b4910f46b04e47b29451059654179ad52009-02-01T00:00:00Zhttps://www.ncbi.nlm.nih.gov/pmc/articles/pmid/19192944/?tool=EBIhttps://doaj.org/toc/1549-1277https://doaj.org/toc/1549-1676<h4>Background</h4>Ovarian cancer has a poor prognosis due to advanced stage at presentation and either intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials with different combinations and sequences of classic cytotoxic drugs indicate that further significant improvement in prognosis by this type of drugs is not to be expected. Currently a large number of drugs, targeting dysregulated molecular pathways in cancer cells have been developed and are introduced in the clinic. A major challenge is to identify those patients who will benefit from drugs targeting these specific dysregulated pathways.The aims of our study were (1) to develop a gene expression profile associated with overall survival in advanced stage serous ovarian cancer, (2) to assess the association of pathways and transcription factors with overall survival, and (3) to validate our identified profile and pathways/transcription factors in an independent set of ovarian cancers.<h4>Methods and findings</h4>According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was performed in duplicate using approximately 35,000 70-mer oligonucleotide microarrays. A continuous predictor of overall survival was built taking into account well-known issues in microarray analysis, such as multiple testing and overfitting. A functional class scoring analysis was utilized to assess pathways/transcription factors for their association with overall survival. The prognostic value of genes that constitute our overall survival profile was validated on a fully independent, publicly available dataset of 118 well-defined primary serous ovarian cancers. Furthermore, functional class scoring analysis was also performed on this independent dataset to assess the similarities with results from our own dataset. An 86-gene overall survival profile discriminated between patients with unfavorable and favorable prognosis (median survival, 19 versus 41 mo, respectively; permutation p-value of log-rank statistic = 0.015) and maintained its independent prognostic value in multivariate analysis. Genes that composed the overall survival profile were also able to discriminate between the two risk groups in the independent dataset. In our dataset 17/167 pathways and 13/111 transcription factors were associated with overall survival, of which 16 and 12, respectively, were confirmed in the independent dataset.<h4>Conclusions</h4>Our study provides new clues to genes, pathways, and transcription factors that contribute to the clinical outcome of serous ovarian cancer and might be exploited in designing new treatment strategies.Anne P G CrijnsRudolf S N FehrmannSteven de JongFrans GerbensGert Jan MeersmaHarry G KlipHarry HollemaRobert M W HofstraGerard J te MeermanElisabeth G E de VriesAte G J van der ZeePublic Library of Science (PLoS)articleMedicineRENPLoS Medicine, Vol 6, Iss 2, p e24 (2009)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R
spellingShingle	Medicine R Anne P G Crijns Rudolf S N Fehrmann Steven de Jong Frans Gerbens Gert Jan Meersma Harry G Klip Harry Hollema Robert M W Hofstra Gerard J te Meerman Elisabeth G E de Vries Ate G J van der Zee Survival-related profile, pathways, and transcription factors in ovarian cancer.
description	<h4>Background</h4>Ovarian cancer has a poor prognosis due to advanced stage at presentation and either intrinsic or acquired resistance to classic cytotoxic drugs such as platinum and taxoids. Recent large clinical trials with different combinations and sequences of classic cytotoxic drugs indicate that further significant improvement in prognosis by this type of drugs is not to be expected. Currently a large number of drugs, targeting dysregulated molecular pathways in cancer cells have been developed and are introduced in the clinic. A major challenge is to identify those patients who will benefit from drugs targeting these specific dysregulated pathways.The aims of our study were (1) to develop a gene expression profile associated with overall survival in advanced stage serous ovarian cancer, (2) to assess the association of pathways and transcription factors with overall survival, and (3) to validate our identified profile and pathways/transcription factors in an independent set of ovarian cancers.<h4>Methods and findings</h4>According to a randomized design, profiling of 157 advanced stage serous ovarian cancers was performed in duplicate using approximately 35,000 70-mer oligonucleotide microarrays. A continuous predictor of overall survival was built taking into account well-known issues in microarray analysis, such as multiple testing and overfitting. A functional class scoring analysis was utilized to assess pathways/transcription factors for their association with overall survival. The prognostic value of genes that constitute our overall survival profile was validated on a fully independent, publicly available dataset of 118 well-defined primary serous ovarian cancers. Furthermore, functional class scoring analysis was also performed on this independent dataset to assess the similarities with results from our own dataset. An 86-gene overall survival profile discriminated between patients with unfavorable and favorable prognosis (median survival, 19 versus 41 mo, respectively; permutation p-value of log-rank statistic = 0.015) and maintained its independent prognostic value in multivariate analysis. Genes that composed the overall survival profile were also able to discriminate between the two risk groups in the independent dataset. In our dataset 17/167 pathways and 13/111 transcription factors were associated with overall survival, of which 16 and 12, respectively, were confirmed in the independent dataset.<h4>Conclusions</h4>Our study provides new clues to genes, pathways, and transcription factors that contribute to the clinical outcome of serous ovarian cancer and might be exploited in designing new treatment strategies.
format	article
author	Anne P G Crijns Rudolf S N Fehrmann Steven de Jong Frans Gerbens Gert Jan Meersma Harry G Klip Harry Hollema Robert M W Hofstra Gerard J te Meerman Elisabeth G E de Vries Ate G J van der Zee
author_facet	Anne P G Crijns Rudolf S N Fehrmann Steven de Jong Frans Gerbens Gert Jan Meersma Harry G Klip Harry Hollema Robert M W Hofstra Gerard J te Meerman Elisabeth G E de Vries Ate G J van der Zee
author_sort	Anne P G Crijns
title	Survival-related profile, pathways, and transcription factors in ovarian cancer.
title_short	Survival-related profile, pathways, and transcription factors in ovarian cancer.
title_full	Survival-related profile, pathways, and transcription factors in ovarian cancer.
title_fullStr	Survival-related profile, pathways, and transcription factors in ovarian cancer.
title_full_unstemmed	Survival-related profile, pathways, and transcription factors in ovarian cancer.
title_sort	survival-related profile, pathways, and transcription factors in ovarian cancer.
publisher	Public Library of Science (PLoS)
publishDate	2009
url	https://doaj.org/article/b4910f46b04e47b29451059654179ad5
work_keys_str_mv	AT annepgcrijns survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT rudolfsnfehrmann survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT stevendejong survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT fransgerbens survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT gertjanmeersma survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT harrygklip survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT harryhollema survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT robertmwhofstra survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT gerardjtemeerman survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT elisabethgedevries survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer AT ategjvanderzee survivalrelatedprofilepathwaysandtranscriptionfactorsinovariancancer
_version_	1718414598394085376

Survival-related profile, pathways, and transcription factors in ovarian cancer.

Ejemplares similares